+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Iodine-123"

Radiopharmaceuticals Market Report and Forecast 2023-2031 - Product Thumbnail Image

Radiopharmaceuticals Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 147 Pages
  • Global
From
Clinical Nuclear Cardiology: Practical Applications and Future Directions - Product Thumbnail Image

Clinical Nuclear Cardiology: Practical Applications and Future Directions

  • Book
  • December 2018
  • 277 Pages
From
Iodine-123 (CAS 15715-08-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Thumbnail Image

Iodine-123 (CAS 15715-08-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • March 2025
  • 50 Pages
  • Global
From
Nuclear Physics 3. Radiopharmaceuticals Used in Nuclear Medicine. Edition No. 1. ISTE Invoiced - Product Thumbnail Image

Nuclear Physics 3. Radiopharmaceuticals Used in Nuclear Medicine. Edition No. 1. ISTE Invoiced

  • Book
  • July 2024
  • 288 Pages
Loading Indicator

Iodine-123 is a radioactive isotope of iodine used in Nuclear Medicine and Radiopharmacology. It is used in a variety of medical imaging procedures, such as thyroid scans, to diagnose and treat thyroid diseases. It is also used in the diagnosis of certain types of cancer, such as neuroendocrine tumors. Iodine-123 has a short half-life of 13.2 hours, making it ideal for use in Nuclear Medicine. It is produced in nuclear reactors and cyclotrons, and is available in a variety of formulations, including capsules, solutions, and injectables. Companies in the Iodine-123 market include GE Healthcare, Mallinckrodt Pharmaceuticals, Jubilant DraxImage, and Bracco Diagnostics. Show Less Read more